Truist Financial Has Lowered Expectations for Disc Medicine (NASDAQ:IRON) Stock Price

Disc Medicine (NASDAQ:IRON) had its price target lowered by research analysts at Truist Financial from $114.00 to $83.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s target price would indicate a potential upside of 24.59% from the stock’s current price.

Several other research firms have also recently issued reports on IRON. Stifel Nicolaus decreased their price objective on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Raymond James Financial reaffirmed a “market perform” rating on shares of Disc Medicine in a research note on Thursday, January 15th. Wells Fargo & Company lowered their price target on Disc Medicine from $109.00 to $78.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 17th. TD Cowen reissued a “buy” rating on shares of Disc Medicine in a research note on Friday, December 19th. Finally, Morgan Stanley set a $75.00 target price on Disc Medicine in a research note on Tuesday, February 17th. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $102.00.

Disc Medicine Price Performance

Shares of IRON opened at $66.62 on Friday. Disc Medicine has a one year low of $30.82 and a one year high of $99.50. The stock’s fifty day moving average is $74.43 and its 200-day moving average is $75.51. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.45 and a current ratio of 23.45. The firm has a market capitalization of $2.51 billion, a price-to-earnings ratio of -11.12 and a beta of 0.88.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.07. The company had revenue of ($19.88) million during the quarter, compared to the consensus estimate of $0.15 million. Equities analysts anticipate that Disc Medicine will post -4.07 EPS for the current year.

Insider Buying and Selling

In related news, insider Rahul Khara sold 6,500 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $78.69, for a total value of $511,485.00. Following the completion of the sale, the insider owned 37,793 shares in the company, valued at approximately $2,973,931.17. This represents a 14.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kevin Bitterman sold 68,923 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $91.24, for a total transaction of $6,288,534.52. Following the completion of the transaction, the director directly owned 14,161 shares of the company’s stock, valued at $1,292,049.64. This represents a 82.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 285,114 shares of company stock valued at $24,937,862. Company insiders own 3.64% of the company’s stock.

Institutional Trading of Disc Medicine

A number of hedge funds have recently modified their holdings of the business. ANTIPODES PARTNERS Ltd purchased a new position in shares of Disc Medicine during the fourth quarter valued at $33,000. Aster Capital Management DIFC Ltd acquired a new stake in Disc Medicine during the 3rd quarter worth about $38,000. CWM LLC boosted its position in Disc Medicine by 213.5% during the 2nd quarter. CWM LLC now owns 1,044 shares of the company’s stock worth $55,000 after acquiring an additional 711 shares during the period. KBC Group NV purchased a new position in Disc Medicine during the 4th quarter valued at about $80,000. Finally, Avanza Fonder AB increased its holdings in shares of Disc Medicine by 54.0% in the 3rd quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock valued at $110,000 after purchasing an additional 585 shares during the period. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine News Summary

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Beat on quarterly results — Disc reported Q4 and full‑year 2025 results with EPS of ($1.62), beating consensus (($1.69)) and provided a business update; the small earnings beat is a short‑term positive signal for execution and guidance clarity. Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst target lowered but rating sustained — Truist cut its price target from $114 to $83 but kept a “buy” rating, signalling continued analyst confidence in the longer‑term thesis despite reduced near‑term expectations. Truist lowers price target to $83
• Neutral Sentiment: Insider sale by CFO — CFO Jean M. Franchi sold 353 shares at ~$69; the sale is small (0.49% reduction in her holdings) and appears routine rather than a clear signal of negative private information. CFO insider sale filing
• Neutral Sentiment: Short‑interest report is inconclusive — a MarketBeat entry shows anomalous/zero short interest data for February (days‑to‑cover 0.0), so there’s no clear short‑squeeze or elevated short pressure signal from this report.
• Negative Sentiment: Restructuring after FDA response — Disc’s board approved a restructuring following an FDA response, implying a regulatory/setback event that prompted corporate changes; this raises near‑term execution and timeline uncertainty for pipeline programs. Disc Medicine Implements Restructuring Following FDA Response
• Negative Sentiment: Investor litigation alert — Pomerantz LLP announced an investigation into Disc Medicine, which can increase legal risk, potential distraction, and perceived governance concerns among investors. Pomerantz investigates Disc Medicine

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.